Skip to main content
Erschienen in: International Journal of Clinical Oncology 6/2019

12.02.2019 | Original Article

Prolonged conservative treatment in patients with recurrent endometrial cancer after primary fertility-sparing therapy: 15-year experience

verfasst von: Yao Wang, Mei Yu, Jia-xin Yang, Dong-yan Cao, Zhen Yuan, Hui-mei Zhou, Ying Zhang, Lei Li, Keng Shen, Huanwen Wu

Erschienen in: International Journal of Clinical Oncology | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Objective

To evaluate the efficacy and prognosis of repeated treatment on patients with recurrent endometrial cancer (EC) after complete remission for primary fertility-preserving therapy.

Materials and methods

We performed a retrospective study of patients with presumed stage IA endometrial cancer who had recurrence after achieving complete remission by fertility-preserving management at the Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, from January 2003 to April 2018. For each patient, medical records and pathology reports were reviewed. The demographic features, treatment efficacy, tumor prognosis, and reproductive outcome were analyzed.

Results

Of the 41 recurrent patients with a median disease-free interval period of 16 months (range, 5–55 months), 23 were diagnosed at recurrence as EC, and 18 were diagnosed as atypical hyperplasia (AH) or endometrial intraepithelial neoplasia (EIN). 26 patients received repeated fertility-preserving treatment, and 23 patients were evaluable for efficacy. The complete response (CR) rate of repeated treatment (19/23, 82.6%) was lower than that of primary fertility-preserving treatment (161/170, 94.7%) with borderline significance (P = 0.053). The CR rate of AH/EIN patients was higher than that of EC patients with no statistical difference (92.9% vs 66.7%, P = 0.260). Among 19 patients achieved CR, 3 got pregnant and delivered successfully, while 3 had a second relapse. Four cases failed to response to the repeated treatment and underwent definitive surgery. 15 patients referred to definitive surgery directly after recurrence and one of them had a pelvic recurrence after 120 months. All patients are alive without evidence of disease at last follow-up.

Conclusions

For patients with recurrent EC after primary fertility-preserving treatment, repeated fertility-preserving treatment can still achieve a promising response and patients have possibilities of completing childbirth.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90CrossRefPubMed Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90CrossRefPubMed
2.
Zurück zum Zitat Chen W, Zheng R, Baade PD et al (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66(2):115–132CrossRefPubMed Chen W, Zheng R, Baade PD et al (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66(2):115–132CrossRefPubMed
3.
Zurück zum Zitat Rackow BW, Arici A (2006) Endometrial cancer and fertility. Curr Opin Obstet Gynecol 18(3):245–252CrossRefPubMed Rackow BW, Arici A (2006) Endometrial cancer and fertility. Curr Opin Obstet Gynecol 18(3):245–252CrossRefPubMed
4.
Zurück zum Zitat Corzo C, Santillan NB, Westin SN et al (2018) Updates on conservative management of endometrial cancer. J Minim Invasive Gynecol 25(2):308–313CrossRefPubMed Corzo C, Santillan NB, Westin SN et al (2018) Updates on conservative management of endometrial cancer. J Minim Invasive Gynecol 25(2):308–313CrossRefPubMed
5.
Zurück zum Zitat Kim YB, Holschneider CH, Ghosh K et al (1997) Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature. Cancer 79(2):320–327CrossRefPubMed Kim YB, Holschneider CH, Ghosh K et al (1997) Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature. Cancer 79(2):320–327CrossRefPubMed
6.
Zurück zum Zitat Ramirez PT, Frumovitz M, Bodurka DC et al (2004) Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol 95(1):133–138CrossRefPubMed Ramirez PT, Frumovitz M, Bodurka DC et al (2004) Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol 95(1):133–138CrossRefPubMed
7.
Zurück zum Zitat Gallos ID, Yap J, Rajkhowa M et al (2012) Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol 207(4):266 e261–e212CrossRef Gallos ID, Yap J, Rajkhowa M et al (2012) Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol 207(4):266 e261–e212CrossRef
8.
Zurück zum Zitat Baek JS, Lee WH, Kang WD et al (2016) Fertility-preserving treatment in complex atypical hyperplasia and early endometrial cancer in young women with oral progestin: is it effective? Obstet Gynecol Sci 59(1):24–31CrossRefPubMedPubMedCentral Baek JS, Lee WH, Kang WD et al (2016) Fertility-preserving treatment in complex atypical hyperplasia and early endometrial cancer in young women with oral progestin: is it effective? Obstet Gynecol Sci 59(1):24–31CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Pronin SM, Novikova OV, Andreeva JY et al (2015) Fertility-sparing treatment of early endometrial cancer and complex atypical hyperplasia in young women of childbearing potential. Int J Gynecol Cancer 25(6):1010–1014CrossRefPubMed Pronin SM, Novikova OV, Andreeva JY et al (2015) Fertility-sparing treatment of early endometrial cancer and complex atypical hyperplasia in young women of childbearing potential. Int J Gynecol Cancer 25(6):1010–1014CrossRefPubMed
10.
Zurück zum Zitat Zhou H, Cao D, Yang J et al (2017) Gonadotropin-releasing hormone agonist combined with a levonorgestrel-releasing intrauterine system or letrozole for fertility-preserving treatment of endometrial carcinoma and complex atypical hyperplasia in young women. Int J Gynecol Cancer 27(6):1178–1182CrossRefPubMed Zhou H, Cao D, Yang J et al (2017) Gonadotropin-releasing hormone agonist combined with a levonorgestrel-releasing intrauterine system or letrozole for fertility-preserving treatment of endometrial carcinoma and complex atypical hyperplasia in young women. Int J Gynecol Cancer 27(6):1178–1182CrossRefPubMed
11.
Zurück zum Zitat Koskas M, Uzan J, Luton D et al (2014) Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis. Fertil Steril 101(3):785–794CrossRefPubMed Koskas M, Uzan J, Luton D et al (2014) Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis. Fertil Steril 101(3):785–794CrossRefPubMed
12.
Zurück zum Zitat Park JY, Lee SH, Seong SJ et al (2013) Progestin re-treatment in patients with recurrent endometrial adenocarcinoma after successful fertility-sparing management using progestin. Gynecol Oncol 129(1):7–11CrossRefPubMed Park JY, Lee SH, Seong SJ et al (2013) Progestin re-treatment in patients with recurrent endometrial adenocarcinoma after successful fertility-sparing management using progestin. Gynecol Oncol 129(1):7–11CrossRefPubMed
13.
Zurück zum Zitat Yamagami W, Susumu N, Makabe T et al (2018) Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility? J Gynecol Oncol 29(2):e21CrossRefPubMedPubMedCentral Yamagami W, Susumu N, Makabe T et al (2018) Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility? J Gynecol Oncol 29(2):e21CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Yu M, Yang JX, Wu M et al (2009) Fertility-preserving treatment in young women with well-differentiated endometrial carcinoma and severe atypical hyperplasia of endometrium. Fertil Steril 92(6):2122–2124CrossRefPubMed Yu M, Yang JX, Wu M et al (2009) Fertility-preserving treatment in young women with well-differentiated endometrial carcinoma and severe atypical hyperplasia of endometrium. Fertil Steril 92(6):2122–2124CrossRefPubMed
15.
Zurück zum Zitat Scully RE, Young RH, Clement PB (1998) Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament, Atlas of Tumor Pathology. Armed Forces Institute of Pathology, Bethesda Scully RE, Young RH, Clement PB (1998) Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament, Atlas of Tumor Pathology. Armed Forces Institute of Pathology, Bethesda
16.
Zurück zum Zitat Perri T, Korach J, Gotlieb WH et al (2011) Prolonged conservative treatment of endometrial cancer patients: more than 1 pregnancy can be achieved. Int J Gynecol Cancer 21(1):72–78CrossRefPubMed Perri T, Korach J, Gotlieb WH et al (2011) Prolonged conservative treatment of endometrial cancer patients: more than 1 pregnancy can be achieved. Int J Gynecol Cancer 21(1):72–78CrossRefPubMed
17.
Zurück zum Zitat Qin Y, Yu Z, Yang J et al (2016) Oral progestin treatment for early-stage endometrial cancer: a systematic review and meta-analysis. Int J Gynecol Cancer 26(6):1081–1091CrossRefPubMed Qin Y, Yu Z, Yang J et al (2016) Oral progestin treatment for early-stage endometrial cancer: a systematic review and meta-analysis. Int J Gynecol Cancer 26(6):1081–1091CrossRefPubMed
18.
Zurück zum Zitat Baker J, Obermair A, Gebski V et al (2012) Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature. Gynecol Oncol 125(1):263–270CrossRefPubMed Baker J, Obermair A, Gebski V et al (2012) Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature. Gynecol Oncol 125(1):263–270CrossRefPubMed
19.
Zurück zum Zitat Kim MK, Yoon BS, Park H et al (2011) Conservative treatment with medroxyprogesterone acetate plus levonorgestrel intrauterine system for early-stage endometrial cancer in young women: pilot study. Int J Gynecol Cancer 21(4):673–677PubMed Kim MK, Yoon BS, Park H et al (2011) Conservative treatment with medroxyprogesterone acetate plus levonorgestrel intrauterine system for early-stage endometrial cancer in young women: pilot study. Int J Gynecol Cancer 21(4):673–677PubMed
20.
Zurück zum Zitat Ushijima K, Yahata H, Yoshikawa H et al (2007) Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 25(19):2798–2803CrossRefPubMed Ushijima K, Yahata H, Yoshikawa H et al (2007) Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 25(19):2798–2803CrossRefPubMed
21.
Zurück zum Zitat Eftekhar Z, Izadi-Mood N, Yarandi F et al (2009) Efficacy of megestrol acetate (megace) in the treatment of patients with early endometrial adenocarcinoma: our experiences with 21 patients. Int J Gynecol Cancer 19(2):249–252CrossRefPubMed Eftekhar Z, Izadi-Mood N, Yarandi F et al (2009) Efficacy of megestrol acetate (megace) in the treatment of patients with early endometrial adenocarcinoma: our experiences with 21 patients. Int J Gynecol Cancer 19(2):249–252CrossRefPubMed
22.
Zurück zum Zitat Parkash V, Fadare O, Tornos C et al (2015) Committee opinion no. 631: endometrial intraepithelial neoplasia. Obstet Gynecol 126(4):897CrossRefPubMed Parkash V, Fadare O, Tornos C et al (2015) Committee opinion no. 631: endometrial intraepithelial neoplasia. Obstet Gynecol 126(4):897CrossRefPubMed
23.
Zurück zum Zitat Signorelli M, Caspani G, Bonazzi C et al (2009) Fertility-sparing treatment in young women with endometrial cancer or atypical complex hyperplasia: a prospective single-institution experience of 21 cases. BJOG 116(1):114–118CrossRefPubMed Signorelli M, Caspani G, Bonazzi C et al (2009) Fertility-sparing treatment in young women with endometrial cancer or atypical complex hyperplasia: a prospective single-institution experience of 21 cases. BJOG 116(1):114–118CrossRefPubMed
24.
Zurück zum Zitat Yamazawa K, Hirai M, Fujito A et al (2007) Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer. Hum Reprod 22(7):1953–1958CrossRefPubMed Yamazawa K, Hirai M, Fujito A et al (2007) Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer. Hum Reprod 22(7):1953–1958CrossRefPubMed
25.
Zurück zum Zitat Navarria I, Usel M, Rapiti E et al (2009) Young patients with endometrial cancer: how many could be eligible for fertility-sparing treatment? Gynecol Oncol 114(3):448–451CrossRefPubMed Navarria I, Usel M, Rapiti E et al (2009) Young patients with endometrial cancer: how many could be eligible for fertility-sparing treatment? Gynecol Oncol 114(3):448–451CrossRefPubMed
26.
Zurück zum Zitat Hurst SA, Hartzfeld KM, Del Priore G (2008) Occult myometrial recurrence after progesterone therapy to preserve fertility in a young patient with endometrial cancer. Fertil Steril 89(3):724.e721–724.e723CrossRef Hurst SA, Hartzfeld KM, Del Priore G (2008) Occult myometrial recurrence after progesterone therapy to preserve fertility in a young patient with endometrial cancer. Fertil Steril 89(3):724.e721–724.e723CrossRef
27.
Zurück zum Zitat Gonthier C, Trefoux-Bourdet A, Koskas M (2017) Impact of conservative managements in young women with grade 2 or 3 endometrial adenocarcinoma confined to the endometrium. Int J Gynecol Cancer 27(3):493–499CrossRefPubMed Gonthier C, Trefoux-Bourdet A, Koskas M (2017) Impact of conservative managements in young women with grade 2 or 3 endometrial adenocarcinoma confined to the endometrium. Int J Gynecol Cancer 27(3):493–499CrossRefPubMed
28.
Zurück zum Zitat Lu KH, Schorge JO, Rodabaugh KJ et al (2007) Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. J Clin Oncol 25(33):5158–5164CrossRefPubMed Lu KH, Schorge JO, Rodabaugh KJ et al (2007) Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. J Clin Oncol 25(33):5158–5164CrossRefPubMed
29.
Zurück zum Zitat Kohlmann W, Gruber SB (2012) Lynch syndrome. In: Pagon RA, Adam MP, Ardinger HH et al (eds) GeneReviews. University of Washington, Seattle Kohlmann W, Gruber SB (2012) Lynch syndrome. In: Pagon RA, Adam MP, Ardinger HH et al (eds) GeneReviews. University of Washington, Seattle
Metadaten
Titel
Prolonged conservative treatment in patients with recurrent endometrial cancer after primary fertility-sparing therapy: 15-year experience
verfasst von
Yao Wang
Mei Yu
Jia-xin Yang
Dong-yan Cao
Zhen Yuan
Hui-mei Zhou
Ying Zhang
Lei Li
Keng Shen
Huanwen Wu
Publikationsdatum
12.02.2019
Verlag
Springer Singapore
Erschienen in
International Journal of Clinical Oncology / Ausgabe 6/2019
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-019-01404-2

Weitere Artikel der Ausgabe 6/2019

International Journal of Clinical Oncology 6/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.